此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares (ACUTE-GO)

2026年11月9日 更新者:ANI Pharmaceuticals

A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares

The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.

Researchers will compare two different doses of Purified Cortrophin Gel.

Participants will:

  • Receive one injection of Purified Cortrophin Gel
  • Have 2 in-person visits to the site and 3 virtual/telephone visits
  • Complete daily surveys about their gout flare

研究概览

研究类型

介入性

注册 (估计的)

160

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Mass General Hospital
        • 首席研究员:
          • Hyon K Choi, MD, DrPH
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 90年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Main inclusion criteria:

  1. Signed informed consent to participate in this study.

  2. Male and female patients, aged 18-90 years.

  3. Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.

  4. Onset of current acute gout flare within 5 days prior to study entry

  5. Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).

  6. History of ≥ 1 gout flares within the 12 months prior to study entry

  7. The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:

    1. Minimum of one episode of inadequate response to treatment.
    2. The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
  8. Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.

Main exclusion criteria:

  1. Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.

  2. Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).

  3. Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.

  4. Patients with sensitivity to proteins derived from porcine sources.

  5. Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.

  6. Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.

  7. Polyarticular gouty arthritis flare currently active in more than 4 joints.

  8. Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.

  9. Previous inclusion in this study.

  10. Patients currently receiving dialysis.

  11. Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.

  12. Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.

  13. Prior or current treatment with any ACTH product.

  14. Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.

    1. Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
    2. Acceptable methods of contraception are:

    i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)

  15. Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.

  16. Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.

  17. Vaccination within 30 days prior to study enrollment and during the study period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
有源比较器:40 U Purified Cortrophin Gel

One injection of Purified Cortrophin Gel, 40 U

有源比较器:80 U Purified Cortrophin Gel

One injection of Purified Cortrophin Gel, 80 U

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in gout pain intensity from baseline in the target joint following PCG administration.
大体时间:From baseline to Day 3

Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

From baseline to Day 3

次要结果测量

结果测量
措施说明
大体时间
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)
大体时间:Baseline to Day 1

Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100

Baseline to Day 1
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)
大体时间:Baseline to Day 2

Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain.

Baseline to Day 2
Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection
大体时间:Baseline to Day 7
Baseline to Day 7
Time to onset of effect (≥20% change from baseline pain intensity on VAS)
大体时间:Baseline to Day 7
Baseline to Day 7
Time to response (≥50% change from baseline pain intensity on VAS)
大体时间:Baseline to Day 7
Baseline to Day 7
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)
大体时间:Baseline to Day 7

Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

Baseline to Day 7
Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)
大体时间:Baseline to Day 3

Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3):

Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome.

Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome.

Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome.

Erythema - categorical assessment: present, absent, or not assessable.

Baseline to Day 3
Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)
大体时间:Baseline to Day 3

Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug.

Baseline to Day 3
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)
大体时间:Baseline to Day 3

Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response.

Baseline to Day 3
Use of rescue medication (up to 72-hours post-injection)
大体时间:Baseline to Day 3
Baseline to Day 3
Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)
大体时间:Baseline to Day 7

Safety will be assessed as follows:

Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug).

Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable).

Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period.

Baseline to Day 7

其他结果措施

结果测量
措施说明
大体时间
Change from Baseline in Serum C-Reactive Protein (CRP) Level
大体时间:Baseline to Day 3

Levels of C-reactive protein inflammatory markers (baseline [Day 0], 72 hours [Day 3]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation

Baseline to Day 3
Change from Baseline in Gout Attack Intensity Score (GAIS)
大体时间:Baseline to Day 3

Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity.

Baseline to Day 3

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月28日

初级完成 (估计的)

2027年11月30日

研究完成 (估计的)

2027年11月30日

研究注册日期

首次提交

2026年3月2日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅